Get started
Award

UM1 AI069494

Funded outputs count: 271
Funder award ID: UM1 AI069494
OpenAlex ID: G6186512954
Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV
2025 · Kristine M. Erlandson, Ariela R. Orkaby, et al. · JACC Advances · 4
Inflammation in frailty, cognitive impairment, clinical events, and mortality among older adults with HIV in the ACTG HAILO cohort
2025 · Win Min Han, Kunling Wu, et al. · AIDS · 3
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
2025 · K. Rachael Parks, Zoe Moodie, et al. · Science Translational Medicine · 50
No evidence of pitavastatin effect on muscle area or density among people with HIV
2025 · Kristine M. Erlandson, Triin Umbleja, et al. · AIDS · 3
No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV
2025 · Kristine M. Erlandson, Ashley McKhann, et al. · AIDS · 6
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
2025 · Carl J Fichtenbaum, Carl J Fichtenbaum, et al. · The Lancet HIV · 12
Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts
2025 · Philip K. Ehrenberg, Aviva Geretz, et al. · Nature Communications · 11
PDF
Prognostic Factors of Physical Function Decline Among Middle-Aged Adults With HIV
2025 · Grace L Kulik, Triin Umbleja, et al. · Open Forum Infectious Diseases · 2
PDF
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trial
2025 · Christopher deFilippi, Aya Awwad, et al. · AIDS · 3
PDF
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy
2025 · Michael T. Lu, Heather J. Ribaudo, et al. · JACC Advances · 9
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
2025 · Cissy Kityo, Caitlyn McCarthy, et al. · Open Forum Infectious Diseases · 2
PDF
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)
2025 · Sharon A. Riddler, Zoe Moodie, et al. · Annals of Internal Medicine · 14
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial
2025 · Marissa R Diggs, Triin Umbleja, et al. · The Lancet HIV · 4
Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid
2025 · Sean N. Avedissian, Ying Mu, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 3
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
2025 · Emma Davies Smith, Carlos Malvestutto, et al. · Open Forum Infectious Diseases · 13
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
2025 · Myra Happe, Rebecca M. Lynch, et al. · JCI Insight · 11
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE
2025 · Steven K Grinspoon, Markella V Zanni, et al. · The Lancet HIV · 36
Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2
2024 · Sydney I. Ramirez, Paul G. Lopez, et al. · JCI Insight · 15
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV
2024 · Márton Kolossváry, Samuel R. Schnittman, et al. · JAMA Cardiology · 16
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse
2024 · Kristen M. Marks, Minhee Kang, et al. · JAMA · 48
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention
2024 · Kathleen V. Fitch, Markella V. Zanni, et al. · Annals of Internal Medicine · 9
PDF
Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV
2024 · Markella V Zanni, Triin Umbleja, et al. · Open Forum Infectious Diseases · 2
Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV
2024 · Edgar T. Overton, Amy Kantor, et al. · AIDS · 5
PDF
Sex-Biased Associations of Circulating Ferroptosis Inhibitors with Reduced Lipid Peroxidation and Better Neurocognitive Performance in People with HIV
2024 · Harpreet Kaur, Ravi Kumar Alluri, et al. · Antioxidants · 5
PDF
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
2024 · Marc-Kendy Paul, Manish Choudhary, et al. · Pathogens and Immunity · 3
Year
Topic